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Abstract 
Purpose: Clinical data collecting is expensive in terms of time and human resources. Data can be collected in different 
ways; therefore, performing multicentric research based on previously stored data is often difficult. The primary objective 
of the ENT COBRA (COnsortium for BRachytherapy data Analysis) ontology is to define a specific terminological system 
to standardized data collection for head and neck (H&N) cancer patients treated with interventional radiotherapy. 
Material and methods: ENT-COBRA is a consortium for standardized data collection for H&N patients treated 
with interventional radiotherapy. It is linked to H&N and Skin GEC-ESTRO Working Group and includes 11 centers 
from 6 countries. Its ontology was firstly defined by a multicentric working group, then evaluated by the consortium 
followed by a multi-professional technical commission involving a mathematician, an engineer, a physician with expe-
rience in data storage, a programmer, and a software expert. 
Results: Two hundred and forty variables were defined on 13 input forms. There are 3 levels, each offering a specific 
type of analysis: 1. Registry level (epidemiology analysis); 2. Procedures level (standard oncology analysis); 3. Research level 
(radiomics analysis). The ontology was approved by the consortium and technical commission; an ad-hoc software architec-
ture (“broker”) remaps the data present in already existing storage systems of the various centers according to the shared ter-
minology system. The first data sharing was successfully performed using COBRA software and the ENT COBRA Ontology, 
automatically collecting data directly from 3 different hospital databases (Lübeck, Navarra, and Rome) in November 2017. 
Conclusions: The COBRA Ontology is a good response to the multi-dimensional criticalities of data collection, 
retrieval, and usability. It allows to create a software for large multicentric databases with implementation of specific 
remapping functions wherever necessary. This approach is well-received by all involved parties, primarily because it 
does not change a single center’s storing technologies, procedures, and habits. 
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Purpose 
Head and neck squamous cell cancers (HNSCC) cur-
rently represent about 4% of the total incidence of malig-
nant diseases in Western countries, with some differences 
related to the primary site [1,2]. 
The reduction of behavioral risk factors, such as 
smoking and alcohol abuse, has indeed validated a de-
crease in the incidence of head and neck (H&N) malig-
nancies, despite the increase of human papilloma virus 
(HPV)-related forms [3,4,5,6,7,8]. 
Some improvements in terms of prognosis have been 
observed in the last three decades, mainly based on sig-
nificant technological developments in diagnostic and 
therapeutic procedures and due to the aforementioned 
increased incidence of HPV positive forms, which are 
generally associated with better prognostic outcomes 
[3,4,8,9,10,11,12,13,14]. 
Furthermore, the quality of life of HNSCC survivors 
has significantly improved due to better functional re-
sults obtained with the current multimodal oncologic 
treatments [15,16,17,18,19,20]. 
The abundance of new options and the progress in 
individualized treatment procedures have created new 
challenges for the modern H&N oncology, in which in-
terdisciplinarity has an important role [21,22,23]. 
In this frame, the possibility to decide a priori which 
treatment will be the best choice for a specific case, both 
in terms of modality (surgery versus conservative treat-
ments) and intensity (radiation dose and technique, drug 
association and surgery extension) is essential. 
Limited number of clinical variables that can be man-
aged by physicians in this difficult decision-making 
process and the absence of dedicated decision support 
systems (DSS) reflect themselves in the use of generic treat-
ment guidelines. These can hardly take into account other 
information as staging of disease according to TNM clas-
sification of malignant tumors (TNM) and its anatomical 
primary site [24]. The evidence, on which these guidelines 
rely on is mainly generated through classical research ap-
proaches, preferably by randomized clinical trials (RCT). 
To date, randomized clinical trials represent the gold 
standard for scientific evidence generation, even if their 
infrastructure still presents some limits, which seem to be 
tough to manage in the era of personalized medicine. Such 
kind of study appears cost intensive and usually requires 
years to be completed. Furthermore, it generally deals only 
with selected subgroups of patients, hardly meeting all the 
characteristics presented by general population. 
The subgroups of patients selected for RCT often do 
not represent specific population groups such as elder-
ly, ethnic minorities, socioeconomic categories, or people 
suffering from specific comorbidities [25,26,27,28]. 
Additionally, RCT data collection is time consuming 
procedure, and needs significant efforts in terms of data 
management and human resources, especially when per-
formed in multi-institutional environments where differ-
ent data feeding and storage procedures have to be con-
sidered. 
The combination of the aforementioned vast amount of 
clinical and molecular data in clinical prediction models, 
nomograms [29], and DSS acquires greater importance, 
and becomes an interesting perspective in the integration 
of this kind of traditional research [30]. 
In this frame, the data standardization process could 
open new possibilities. The overriding position of RCT, 
gaining importance to reach higher dataset quality, and 
reduce its entropy – a common ontology table, shared by 
the different involved institutions could be the solution. 
As stated in previous analyses, an ‘ontology’ represents 
knowledge as a set of concepts within a domain and the re-
lationships between those concepts [30,31]. In practice, an 
ontology represents a classification system, in which every 
variable (in this case specifically related to the domain of 
patients affected by head and neck malignancies) can be 
represented through uniform and explicit definitions. 
The use of ontologies agreed by the different data 
originating centers can successfully enhance the deep un-
derstanding of datasets and the correct utilization of data, 
as the ontological relationships can address variables de-
fining space (e.g., relationships between institutional and 
standard terminologies) and time (e.g., consecutive ver-
sions of different classification systems). 
By this approach, clinical research on H&N cancer will 
be characterized by a better and less ambiguous under-
standing of considered variables without differences in 
storage and interpretation. This data collection model can 
also increase the number of variables that can be collected 
over time, comprehending in the dataset all the clinical, 
therapeutic and technical developments, and updates 
[32,33]. The quality of collected data can be significantly 
improved by the standardized data collection (SDC) ap-
proach defining which variables should be collected and 
regulating the most appropriate ways to measure them. 
In a previous publication, the characteristics of the 
COBRA consortium have been described along with the 
features of the software used to collect and share multi-in-
stitutional data [30]. 
Aim of the present work is to explain and describe the 
efforts conducted by the Groupe Européen de Curiethéra-
pie-ESTRO Head & Neck and Skin Working Group (GEC- 
ESTRO H&N WG), in order to define a commonly shared 
ontology for SDC purposes as well to present the results of 
the first round of data sharing through the privacy-preserv-
ing system, which was developed for this purpose. 
Material and methods 
The Groupe Européen de Curiethérapie – European 
Society for Radiotherapy & Oncology Head & Neck and 
Skin Working Group (GEC-ESTRO H&N and Skin WG) 
started the H&N COBRA project, approving its structure, 
and defining its milestones: the consortium agreement, 
ontology, and the minimal requirements for each center 
to join the project. 
The ontology was defined by a task group (LT, AB, GK), 
and a technical commission (TeCo) composed by a mathe-
matician (AD), an engineer (RG), a physicist with experience 
in data storage (JL), a physician with experience in data stor-
age (ND), and a software expert (VL). 
This multi-professional group stated the characteris-
tics that the ontology had to meet in order to be accepted. 
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These requirements included the definition of the data 
type for each field, the possible values allowed, the cardi-
nality of the items (i.e., single-select or multi-select field), 
and the allowed range in the case of numerical values. 
Also, the taxonomic semantics of particular hierar-
chical fields were explicit requirements in order to merge 
into the ontology some semantic annotations that could 
be extended and exploited for performing inference in 
the data on a later moment. 
From the point of view of semantics, a link to the 
actual clinical phase was defined for each field in the 
ontology. For instance, information about a particular 
treatment (e.g., dose administered, dose rate, date of 
administration) includes in their meta-data the notion 
of whether it has been administered for neoadjuvant 
or adjuvant purposes. In general, all the requirements 
defined by the consortium aim to define as precise as 
possible all the knowledge that characterizes the phy-
sicians’ specialized lexicon (http://www.openclinical.
org/ontologies.html). 
Following the formal definition of the ontology and 
its requirements, the task group and the TeCo were asked 
to define the tools for sharing the ontology among the 
centers in a standardized form. In order to accomplish 
this task, the “beyond ontology awareness” (BOA) soft-
ware, capable to reproduce the structure of the ontology, 
manage the legacy data import, and coordinate data shar-
ing activities was developed [30,34]. 
All the centers joining the consortium were required to: 
1. Install the software with the ontology-compliant case 
report forms (CRFs) in their servers: the file needed 
for the installation and setup of both the software and 
the database, along with a manual to drive the user 
through this process, were shared among the consor-
tium members via dropbox folders. 
2. Upload legacy data into the software’s database: 
a spreadsheet template compliant with the ENT-COBRA 
ontology definitions was sent to the participants, so 
that they could fill it with their data. After that, the 
participants were required to do a simple mapping be-
tween this spreadsheet’s columns and the actual fields 
in the ontology database. The mapping and the subse-
quent data import were performed through BOA. 
3. Test the connection to the centralized repository for 
data sharing: once the legacy data had been imported 
in the local ontology database, the participants were 
asked to test their connection to the central repository. 
4. Share the data according to the agreed procedure: by 
means of a dedicated software tool in BOA, the data 
were anonymized, encrypted, and sent to the central 
repository via a secure, https-based, web service. 
The above-mentioned tasks were performed by desig-
nated members of the participant centers with the assis-
tance of the consortium technical team. 
Results 
Ontology definition and implementation 
They were eleven centers of research joining the con-
sortium in total. The characteristics of the ontology were 
defined by the TeCo committee and subsequently, they 
were released an Excel (Excel, Microsoft) template con-
taining all the properties that each field had to be associat-
ed with. These properties were defined to be: item name, 
description label, units of measurement when applicable, 
item number, response option text when applicable (val-
ues of tabular fields), response option value (identifiers 
of response option text), cardinality of response options 
(single-select or multi select fields), data type, validation 
pattern, a flag to state if the field is a required one. More-
over, each field was defined to be associated to the actual 
therapeutic phase, in which it is recorded: this association 
is stored in the ‘CRF name’ property of each field. 
Number of the defined variables was 240. Each variable 
presents 4 properties: name, form, type of field, and lev-
els. Thirteen forms were proposed: 1. Registry and history; 
2. Histology; 3. Staging; 4. Protocol; 5. Surgery; 6. External 
beam radiotherapy; 7. Neoadjuvant chemotherapy (CT); 
8. Concomitant CT; 9. Adjuvant CT; 10. Brachytherapy; 
11. Follow-up (repeated); 12. Outcome (automatically cal-
culated based on follow-up); 13. Images and treatment files. 
Field types were: text, number, date, table, files. 
The chosen standard file formats are “DICOM” for im-
age and “TXT files” for data treatment. All tables linked 
with variables are defined. The toxicity is stored with 
common terminology criteria for adverse events version 4 
(CTCAE v. 4.0) scale, and the Radiation Therapy Oncolo-
gy Group/ EORTC acute and late toxicity scale (RTOG/ 
EORTC) (for back comparison with retrospective stud-
ies). The RTOG/EORTC scale choice was a forced one, as 
many data are stored using this scale and a direct map-
ping with CTCAE v. 4.0 is not possible. 
There are 3 levels data, each allowing a specific type of 
analysis: 1. Registry level (epidemiology analysis); 2. Pro-
cedures level (standard oncology analysis); 3. Research 
level (radiomics analysis). The variables of “registry lev-
el” are: patient’s code, date of birth, gender, ethnicity, 
age, cancer site, multidisciplinary management, institu-
tion, histology type, therapy sequence, death, death date, 
cause of death. The third level includes image files and 
all other variables are in the “procedures” level. All the 
characteristics of the ontology can be found in the supple-
mentary material of this paper. 
Software installation and data-sharing 
The ontology was proposed by the task force and 
accepted after internal discussion of the consortium fol-
lowed by the technical committee (TeCo) approval. 
Out of a total number of 11 centers joining the consor-
tium, five had installed the software properly and three of 
them had successfully imported their legacy data into the 
COBRA-ontology compliant archive from internal hospi-
tal databases (local ethic committee protocol approval was 
needed). 
These centers did not modify their data collection 
policy, as the software imported the data directly from 
their database sorting the information according to the 
ontology. These three centers succeeded in sending 
anonymized and encrypted data into the cloud-based 
repository through procedure agreed by the consor-
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tium. The first proof run of machine learning analysis 
took place based on the information coming from these 
3 ready centers. Further analyses are scheduled in the 
next future, aiming to obtain more data from the partic-
ipating 3 centers and to involve those that will be ready 
later on. 
The three steps of installation, data-import, and data 
sharing were performed by each center using the guide-
lines that were provided with the software, and only one 
remote assistance session was needed by each center 
per task. No on-site intervention was needed for any of 
the three tasks and the procedure proved to be straight-
forward. During the installation procedure in the third 
center, one problem with the data import was identified. 
The programmer found a bug in the system and the soft-
ware code was modified accordingly. No data had been 
shared before this episode, so that data were correctly 
imported in the cloud following the consortium rules as 
well Italian and European laws in respect of the patient’s 
privacy. Whereas local legislation involving patient pri-
vacy, data ownership, or other issues make data sharing 
not feasible, a solution based on PPDM (privacy preserv-
ing data mining) [35,36,37] has been developed and im-
plemented. The solution is based on a distributed ecosys-
tem, including preliminary analysis, distributed learning 
and validation, in a rapid learning framework, enabling 
researchers to learn and validate predictive models with-
out patient data leaving the institution, where they had 
been collected in the first place [37]. 
Epidemiology analysis on the shared data 
The first data sharing allowed to run a descriptive 
analysis of the combined data coming from the three par-
ticipants centers. To this purpose, a subset of the shared 
covariates was selected, which included gender, type of 
histology, date of histology, cancer site, brachytherapy 
start date, brachytherapy technique. The total number 
of patients after the data sharing was 325, with center 
A (Lubeck) contributing 222 patients, center B (Navarra) 
with 63 patients, and center C (Rome) with 40 patients. 
The overall dataset contained 10 different histology 
types, with dates of histology analysis ranging from Jan-
uary 2001 to December 2016. Nineteen different cancer 
sites were also found and 2 different brachytherapy tech-
niques, with the corresponding brachytherapy start dates 
ranging from February 2001 to March 2017. 
Tables 1-4 show in detail the characteristics of the cat-
egorical covariates, namely gender, histology type, cancer 
site (ID9), and brachytherapy technique, on the overall 
dataset. 
Discussion 
These results are certainly encouraging from the per-
spective of improving clinical research quality, efficiency, 
and effectiveness. In fact, once the single center is connect-
ed through this approach to all the other centers, thanks to 
the legacy data import procedure, it can continue collect-
ing data in its usual way and at the same time, it is able to 
participate to larger research projects without sustaining 
the related high costs. The data collected in a single center 
are indeed semi-automatically translated into the ontology 
and the platform allows to easily select groups of patients 
and/or groups of covariates to be anonymized, encrypted, 
and sent to the shared repository, where machine learning 
algorithms are launched on these large multicentric data-
sets to build and validate predictive models. 
The platform can also allow each center to participate 
in learning runs in a distributed way, meaning that each 
center’s data stay in the center’s own server, and it is the 
centralized machine learning algorithm to send back and 
forth the parameters for learning and validating the mod-
el until convergence and consensus is reached among 
participants centers. 
Moreover, besides improvements in quality, efficiency, 
and effectiveness, it is not obvious that a single center has 
the resources or the will to hire statisticians, physicians, 
and engineers in order to build software, analyze data, 
and produce decision support systems (DSS) useful for the 
clinical practice. Thus, a positive outcome of this effort to 
produce SDC in a machine learning framework would be 
gaining the chance to have ready-made, software-embed-
ded, peer-validated predictive models with as low cost as 
possible for all the centers joining the consortium. 
The Authors believe that this ontology is a good an-
swer to a multi-dimensional problem that involves data 
collection, retrieval, and usability. 
Table 1. Number of occurrences and frequencies 
for ‘gender’ values in the cloud-shared database 
Gender value # of occurrences %
Male 226 69.6
Female 98 30.1
Not available 1 0.3
Table 2. Number of occurrences and frequencies 
for ‘histology type’ values in the cloud-shared 
database 
Histology type value # of occurrences %
Squamous cell carcinoma 272 84
Adenocarcinoma 19 6
Lymphoepithelioma 10 3
Soft tissue tumors and sarcomas 8 2.5
Basal cell neoplasms 7 2.1
Nevi and melanomas 4 1.2
Cystic, mucinous, and serous 
neoplasms
2 0.6
Blood vessel tumors 1 0.3
Mucoepidermoid neoplasms 1 0.3
Undifferentiated carcinoma 1 0.3
Not available 0 0
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Multicenter data collection, especially with interna-
tional project participants, is expensive both in terms of 
human resources allocation and time spent to perform 
various tasks. Additionally, national and international 
law needs to be respected in cases, in which some steps 
toward process optimization has been taken, and differ-
ent terms of clinical practice needs to be involved. This is 
even more accurate, if collected data are used only once 
and then discarded. 
The described procedures with clinical data make 
them available and reusable also in the future, in dif-
ferent places and by various researchers, and with the 
freedom of the use in different research contexts apart of 
those where they were firstly collected. This also means 
that more ambitious researches can be conducted, as pa-
tients from many institutions are grouped together, the 
involved numbers can be easily increased by at least one 
order of magnitude. 
The level of the so produced evidence will be defined 
on a case by case basis, as it will depend on the selected 
ontologies and on the chosen research setting (e.g., pro-
spective or retrospective). 
Furthermore, all the traditional levels of evidence for 
therapeutic studies could be theoretically met through 
this approach and modulated by this dynamic framework 
that will allow the setup of predictive models, whose reli-
ability can be defined by the TRIPOD criteria [38,39]. 
This new approach will also enable us to conduct re-
searches with more simultaneous parameters, thus an-
swering a pressing issue within the scientific community. 
The different research contexts mean that our analysis re-
sults can be useful for studies that we cannot even imag-
ine today, also giving a practical answer to the great issue 
of validation, where researchers want to confirm a new 
model and often struggle to find suitable data. 
The potential clinical relevance of this project remains 
to date not directly foreseeable, as it strongly depends on 
investigators usage of this new research approach as a prac-
tical tool to enhance the quality of the produced scientific 
evidence enriching the actual power of RCT and allowing 
to build a more dynamic research context, with clinical data 
improved by patient reported outcomes obtained through 
e-medicine techniques and personal devices [40]. 
Conclusions 
The ENT COBRA Ontology represents therefore 
a good answer to the multi-dimensional issues concern-
ing data collection, retrieval, and usability. This allows to 
create software for large multicentric databases with the 
implementation of specific remapping functions. The latter 
seem to be well received by all involved parties, primarily 
because this approach does not change the center’s storing 
technologies, procedures, and habits. A further improve-
ment is possible, in which privacy preserving data mining 
is implemented via distributed learning and validation, 
enabling learning predictive models without moving pa-
tient data from their collecting site. 
Disclosure
The authors declare no conflict of interest. 
Table 3. Number of occurrences and frequencies 
for ‘cancer site (ICD9)’ values in the cloud-shared 
database 
Cancer site value (ICD9) # of occurrences %
141 Malignant neoplasm of tongue 94 28.9
146 Malignant neoplasm  
of oropharynx 
58 17.8
160 Malignant neoplasm of nasal 
cavities, middle ear, and accessory 
sinuses 
40 12.3
161 Malignant neoplasm of larynx 35 10.8
147 Malignant neoplasm  
of nasopharynx
19 5.8
148 Malignant neoplasm  
of hypopharynx 
16 4.9
144 Malignant neoplasm  
of floor of mouth 
14 4.3
145 Malignant neoplasm of other 
and unspecified parts of mouth 
12 3.7
173 Other malignant neoplasm 
of skin
9 2.8
172 Malignant melanomas of skin 6 1.8
142 Malignant neoplasm of major 
salivary glands
6 1.8
190 Malignant neoplasm of eye 4 1.2
171 Malignant neoplasm of con-
nective and other soft tissue
3 0.9
143 Malignant neoplasm of gum 2 0.6
199 Malignant neoplasm without 
specification of site
2 0.6
153 Malignant neoplasm of colon 2 0.6
238 Neoplasm of uncertain behav-
ior of other and unspecified sites 
and tissues
1 0.3
192 Malignant neoplasm of other 
and unspecified parts of nervous 
system
1 0.3
158 Malignant neoplasm of retro-
peritoneum and peritoneum
1 0.3
Not available 0 0
Table 4. Number of occurrences and frequencies 
for ‘brachytherapy technique’ values in the cloud- 
shared database 
Brachytherapy technique value # of occurrences %
Interstitial 310 95.4
Intracavitary 15 4.6
Not available 0 0
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